Idarubicin

Generic Name: Idarubicin

Brand Names: Idamycin

Drug Type: Small Molecule

Chemical Formula: C_₂₆H_₂₇NO_₉

CAS Number: 58957-92-9

Unique Ingredient Identifier: ZRP63D75JW

Background: An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity.

Indication: For the treatment of acute myeloid leukemia (AML) in adults. This includes French-American-British (FAB) classifications M1 through M7.

Associated Conditions: Acute Myeloid Leukemia

Associated Therapies: -

Clinical Trials

Thalidomide, Cyclophosphamide, Oral Idarubicin and Dexamethasone (T-CID) in Patients With Multiple Myeloma

Phase 2

Conditions: Multiple Myeloma

First Posted Date: 2005-07-28

Last Posted Date: 2010-02-02

Lead Sponsor: University Hospital, Bonn

Target Recruit Count: 80

Registration Number: NCT00124813

Locations: 🇩🇪
Medical Clinic & Policlinic III, University of Bonn, Bonn, Germany

Pravastatin, Idarubicin, and Cytarabine in Treating Patients With Acute Myeloid Leukemia

Phase 1

Completed

Conditions: Leukemia

First Posted Date: 2005-04-06

Last Posted Date: 2010-09-21

Lead Sponsor: Fred Hutchinson Cancer Center

Registration Number: NCT00107523

Locations: 🇺🇸
M.D. Anderson Cancer Center at University of Texas, Houston, Texas, United States
🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Phase 2

Terminated

Conditions: Adult Acute Basophilic Leukemia
Adult Acute Eosinophilic Leukemia
Adult Acute Megakaryoblastic Leukemia (M7)
Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Adult Acute Monoblastic Leukemia (M5a)
Adult Acute Monocytic Leukemia (M5b)
Adult Acute Myeloblastic Leukemia With Maturation (M2)
Adult Acute Myeloblastic Leukemia Without Maturation (M1)
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myelomonocytic Leukemia (M4)

Interventions: Drug: idarubicin
Drug: cytarabine
Other: laboratory biomarker analysis
Biological: bevacizumab

First Posted Date: 2004-11-09

Last Posted Date: 2013-01-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 120

Registration Number: NCT00096148

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia

Phase 1

Completed

Conditions: Adult Acute Myeloblastic Leukemia With Maturation (M2)
de Novo Myelodysplastic Syndromes
Untreated Adult Acute Myeloid Leukemia
Adult Acute Monoblastic Leukemia (M5a)
Adult Acute Monocytic Leukemia (M5b)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Adult Pure Erythroid Leukemia (M6b)
Childhood Myelodysplastic Syndromes
Adult Acute Eosinophilic Leukemia
Adult Acute Minimally Differentiated Myeloid Leukemia (M0)

Interventions: Drug: cytarabine
Drug: idarubicin
Drug: tipifarnib

First Posted Date: 2004-11-09

Last Posted Date: 2014-05-26

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 95

Registration Number: NCT00096122

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Arsenic Trioxide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia

Phase 1

Completed

Conditions: Leukemia

First Posted Date: 2004-10-08

Last Posted Date: 2014-01-13

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 61

Registration Number: NCT00093483

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia or Acute Leukemia

Phase 2

Completed

Conditions: Leukemia

First Posted Date: 2004-09-16

Last Posted Date: 2013-05-30

Lead Sponsor: Loyola University

Registration Number: NCT00004905

Locations: 🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸
Loyola University Medical Center, Maywood, Illinois, United States

Monoclonal Antibody Therapy and Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia in Remission

Phase 2

Completed

Conditions: Leukemia

First Posted Date: 2004-08-11

Last Posted Date: 2013-06-24

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 40

Registration Number: NCT00002609

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Peripheral Stem Cell Transplantation Plus Filgrastim in Treating Patients With Acute or Chronic Myelogenous Leukemia

Phase 2

Completed

Conditions: Graft Versus Host Disease
Leukemia
Myelodysplastic Syndromes

Interventions: Biological: Filgrastim
Drug: Cladribine
Drug: Cyclosporine
Drug: Cytarabine (Ara-C)
Drug: Fludarabine Phosphate
Drug: Idarubicin
Drug: Methylprednisolone
Procedure: Peripheral Blood Stem Cell Transplantation

First Posted Date: 2004-07-30

Last Posted Date: 2012-07-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 53

Registration Number: NCT00002833

Locations: 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Acute Myelogenous Leukemia

Phase 3

Conditions: Leukemia

First Posted Date: 2004-07-19

Last Posted Date: 2009-12-23

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 1520

Registration Number: NCT00002549

Locations: 🇵🇹
Hospitais da Universidade de Coimbra (HUC), Coimbra, Portugal
🇨🇿
Institute of Hematology and Blood Transfusion, Prague, Czech Republic
🇧🇪
Algemeen Ziekenhuis Middelheim, Antwerp, Belgium

and more 72 locations

Combination Chemotherapy With or Without Interferon Alfa in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma

Phase 3

Conditions: Lymphoma

First Posted Date: 2004-07-16

Last Posted Date: 2013-09-17

Lead Sponsor: Scotland and Newcastle Lymphoma Group

Target Recruit Count: 200

Registration Number: NCT00003639

Locations: 🇬🇧
Royal Victoria Infirmary, Newcastle-upon-Tyne, England, United Kingdom

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy